NAVIGEN, INC.

Address

383 Colorow Drive
SALT LAKE CITY, UT, 84108-1201

http://www.nvgn.com

Information

DUNS: 792046224
# of Employees: 19

Ownership Information

Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N

Award Charts




Award Listing

  1. Preclinical development of a potent D-peptide RSV inhibitor

    Amount: $992,263.00

    PROJECT SUMMARY Respiratory syncytial virus RSV is the major cause of severe lower respiratory tract infections in children and infants affecting an estimated million people and causing up to ...

    SBIRPhase II2016Department of Health and Human Services
  2. Highly specific anti-toxin therapies for severe bacterial gut infections

    Amount: $597,344.00

    DESCRIPTION provided by applicant Shiga toxins and Stx are the primary virulence factors of Shiga toxin producing E coli STEC which are major food and waterborne pathogens afflicting ...

    SBIRPhase I2015Department of Health and Human Services
  3. Arf6 inhibitors for the treatment of uveal melanoma

    Amount: $298,731.00

    DESCRIPTION provided by applicant Activating mutations in G proteins are the drivers of oncogenesis in numerous cancers Therefore identifying drugs that block the signaling pathways controlled b ...

    SBIRPhase I2015Department of Health and Human Services
  4. Treating Acute Lung Injury via Cytokine Signaling Blockade

    Amount: $224,632.00

    DESCRIPTION provided by applicant Acute lung injury ALI and acute respiratory distress syndrome ARDS result from a common pathogenic process pulmonary injury or infection triggers an overwhelm ...

    SBIRPhase I2015Department of Health and Human Services
  5. Developing a Peripherally-Acting Peptidic Galanin Analog for Treatment of Postoperative Pain

    Amount: $290,919.00

    DESCRIPTION provided by applicant The development of non opioid analgesics for the control of postsurgical pain is widely acknowledged as an important goal The side effects of opioids most notabl ...

    SBIRPhase I2015Department of Health and Human Services
  6. Protease-resistant D-peptide Inhibitors of Ebola Virus Entry

    Amount: $2,894,941.00

    DESCRIPTION provided by applicant Ebola virus causes highly lethal hemorrhagic fever in humans and non human primates Since the first outbreak in there have been over natural human outbre ...

    SBIRPhase II2015Department of Health and Human Services National Institutes of Health
  7. Blocking a novel cytokine signaling pathway for the treatment of rheumatoid arthr

    Amount: $1,502,644.00

    DESCRIPTION provided by applicant In spite of remarkable progress in management of rheumatoid arthritis RA a devastating autoimmune disease that affects million Americans causing chronic inf ...

    SBIRPhase II2014Department of Health and Human Services
  8. CT-based Biomarker for Diagnosis of COPD Phenotypes and Disease Progression

    Amount: $145,269.00

    DESCRIPTION (provided by applicant): Rheumatoid arthritis (RA) affects approximately 1.3 million adults in the United States and up to 1.5% of the population worldwide. In its progressive form the dis ...

    SBIRPhase I2013Department of Health and Human Services
  9. Identification of novel small molecule inhibitors of Arf6 for the treatment of va

    Amount: $150,640.00

    DESCRIPTION (provided by applicant): Age-Related Macular Degeneration is the most common cause of legal blindness in people over 60, affecting an estimated 1.6 million patients. Additionally, over 400 ...

    SBIRPhase I2013Department of Health and Human Services
  10. Therapeutic D-peptide Inhibitor of HIV Entry

    Amount: $3,000,000.00

    DESCRIPTION provided by applicant With million people living with HIV AIDS including million in the US and million AIDS related deaths annually HIV AIDS remains a formidable global epidemic UNAIDS CDC ...

    SBIRPhase II2013Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government